Skip to content
Evigrade
CriticalErgot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist×Triptan, selective 5HT1B/1D receptor agonist

Updated · Methodology

Mechanism

Both drugs constrict blood vessels. Frovatriptan is a selective agonist of 5-HT1B and 5-HT1D serotonin receptors and is thought to prevent excessive dilation of cranial arteries during migraine (frovatriptan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Frovatriptan can cause coronary artery spasm even in people without coronary artery disease (frovatriptan label, US Food and Drug Administration, FDA). Dihydroergotamine, an ergotamine derivative, binds to 5-HT1D receptors, and its main metabolite is as potent a venoconstrictor as the parent drug. Like other ergot alkaloids, dihydroergotamine can cause spasm of the coronary and other arteries (dihydroergotamine labels, FDA). According to the Spanish frovatriptan SmPC, when frovatriptan is taken with ergotamine or its derivatives for the same migraine attack, their vasoconstrictor effects add up, with a risk of raised blood pressure and coronary artery spasm (AEMPS). The US label states that ergot drugs cause prolonged vasospasm that may add to the effect of frovatriptan (FDA). The documents give no data on drug levels with dihydroergotamine itself, while with ergotamine the area under the concentration curve and peak concentration of frovatriptan fell by about 25% (frovatriptan label, FDA).

Symptoms

Transient chest pain and tightness can occur after frovatriptan and may be intense and spread to the throat (frovatriptan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Such sensations in the chest, throat, neck and jaw are usually not cardiac, but rare cases of myocardial infarction have been reported within a few hours of frovatriptan, including in people without known coronary artery disease. Ventricular tachycardia and ventricular fibrillation have been reported within a few hours of drugs of this class, and myocardial infarction, life-threatening arrhythmias and transient myocardial ischaemia after dihydroergotamine (frovatriptan and dihydroergotamine labels, US Food and Drug Administration, FDA). Spasm of other arteries shows as abdominal pain with bloody diarrhoea from bowel ischaemia, splenic infarction and Raynaud's syndrome, and with dihydroergotamine as muscle pain, numbness, coldness, pallor and bluish discolouration of the fingers and toes. In people with poor circulation, persistent vasospasm can lead to gangrene or death (frovatriptan and dihydroergotamine labels, FDA). On rare occasions blood pressure has risen markedly after dihydroergotamine and after drugs of the frovatriptan class, and hypertensive crisis with acute organ damage has been reported with the latter (dihydroergotamine and frovatriptan labels, FDA).

Management

The combination is contraindicated. The Spanish frovatriptan summary of product characteristics (SmPC) contraindicates frovatriptan with ergotamine and ergotamine derivatives (frovatriptan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). However, the authorisation of this product, the only frovatriptan product in Spain, was revoked in May 2024, and dihydroergotamine is not in the Spanish medicines register. The US frovatriptan label contraindicates dihydroergotamine by name if less than 24 hours separate the two drugs (frovatriptan label, US Food and Drug Administration, FDA). The dihydroergotamine labels contraindicate dihydroergotamine in patients who have taken triptans in the previous 24 hours and name frovatriptan among them (dihydroergotamine labels, FDA). Keep at least 24 hours between the two drugs, in either order (frovatriptan SmPC, AEMPS, and label, FDA). If chest pain or tightness suggesting cardiac ischaemia appears after a frovatriptan dose, withhold further doses and investigate further (frovatriptan SmPC, AEMPS). Stop frovatriptan if arrhythmias occur (frovatriptan label, FDA). Stop dihydroergotamine at once if signs of vasoconstriction appear (dihydroergotamine labels, FDA), and rule out vasospasm before frovatriptan is taken again (frovatriptan label, FDA). Monitor blood pressure during frovatriptan treatment (frovatriptan label, FDA). Frovatriptan is contraindicated in severe or moderate hypertension and in uncontrolled mild hypertension (AEMPS), and dihydroergotamine in uncontrolled hypertension (dihydroergotamine labels, FDA). Taking triptans and ergot drugs, alone or together, on 10 or more days a month can lead to medication overuse headache (frovatriptan and dihydroergotamine labels, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dihydroergotamine

Other interactions with Frovatriptan